Beale K.K., Robinson WE Jr. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drugsensitive and RT inhibitor-resistant molecular clones of HIV-1. Antiviral Res. 2000; 46:223-32.
Boldescu V, Behnam MAM, Vasilakis N, Klein CD. Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond. Nat Rev Drug Discov. 2017; 16:565- 586.
BRASIL. Ministério da Saúde. COVID-19 NO BRASIL. Dados do setor. Brasília, 2020. Disponível em: https://susanalitico.saude.gov.br/extensions/covid-19_html/covid- 19_html.html. Acesso em: 10/07/2020.
Caly, L; Julian D. Druce, Mike G. Catton, David A. Jans, Kylie M. Wagstaff,The FDA- approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro,Antiviral Research,Volume 178,2020,104787,ISSN 0166-3542,https://doi.org/10.1016/j.antiviral.2020.104787.(http://www.sciencedirect.com/science/article/pii/S0166354220302011.
Cao B, Wang Y, Wen D,et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 Mar 18. doi: 10.1056/NEJMoa2001282.
Crooks G.E., Hon G, Chandonia JM, Brenner SE WebLogo: A sequence logo generator,Genome Research, 14:1188-1190, (2004).
Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot (Tokyo). 2017 May;70(5):495-505.
Eduardo S. Uso de inibidores da integrase como agentes de primeira linha no tratamento da infecção pelo HIV. BJID. Educação Médica Continuada. Vol 2 • Nº 4 • Agosto 2016. Disponivel em: https://www.elsevier.es/pt-revista-the-brazilian-journal- infectious-diseases-269-articulo-uso-inibidores-da-integrase-como- X2177511716574464. Acessafo em: 06 de julho de 2020.
Ferner R.E., Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S.A., Palese, P., Baric, R.S., Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgimembrane, J Virol, 81 (18) (2007), pp. 9812-9824.
Grein J, Ohmagari N, Shin D, Compassionate Use of Remdesivir for Patients with Severe Covid19. N Engl J Med. 2020 Apr 10. doi:10.1056/NEJMoa2007016.
Kumar S, Stecher G, Li M, Knyaz C, and Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. (2018). Molecular Biology and Evolution 35:1547-1549.
Nei M. and Kumar S. (2000). Molecular Evolution and Phylogenetics. Oxford University Press, New York.
OMS. Organização Mundial de Saúde. Genebra: OMS, 2020.
Patel, A.N; Desai, S.S.; Grainger, D.W.; Mehra, M.R. 2020. Usefulness of Ivermectin in COVID-19 Illness. Disponível em: https://www.google.com/url?sa=t&source=web&rct=j&url=http://www.proyectodime.i nfo/documents/219/Utilidad_de_la_ivermectina.pdf&ved=2ahUKEwjOjJ- SudTpAhUaCrkGHahuAxkQFjAHegQICBAB&usg=AOvVaw2dLQryr8gQxSZFATZv YSo3. Acessado em 15/06/2020.
Puras Lutzke RA, Eppens NA, Weber PA, et al. Identification of a hexapeptide inhibitor of the human immunodeficiency vírus integrase protein by using a combinatorial chemical library. Proc Natl Acad Sci USA. 1995; 92:11456-60.
Reinke R1, Steffen NR, Robinson WE Jr. Natural selection results in conservation of HIV-1 integrase activity despite sequence variability. AIDS. 2001; 15:823-30.
Robinson WE Jr. L-chicoric acid, an inhibitor of human immunodeficiency vírus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350). Antiviral Res. 1998; 39:101-11.
Schneider TD, Stephens RM. 1990. Sequence Logos: A New Way to Display Consensus Sequences. Nucleic Acids Res. 18:6097-6100.
Smart T. The first integrase inhibitor. GMHC Treat Issues. 1996; 10:8-9.
Tamura K. (1992). Estimation of the number of nucleotide substitutions when there are strong transition-transversion and G + C-content biases. Molecular Biology and Evolution 9:678-687.